20.53 +0.26 (1.27%)
After hours: 4:47PM EST
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||20.26 - 20.62|
|52 Week Range||17.68 - 22.42|
|PE Ratio (TTM)||30.67|
|Earnings Date||Feb 5, 2018 - Feb 9, 2018|
|Forward Dividend & Yield||0.24 (1.17%)|
|1y Target Est||20.60|
Cooper Companies (COO) continues to witness impressive results at the CooperVision business segment that delivered strong sales in Q4.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Luminex Corp. a score of 69. Our analysis is based on comparing Luminex Corp. with the following peers – Illumina, Inc., Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc. Class A, Abbott Laboratories, Hologic, Inc., Pacific Biosciences of California, Inc., NanoString Technologies, Inc. and ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Luminex Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
BioTelemetry (BEAT) is consistently trying to improve its position in the cardiac monitoring and diagnostic services space.
Flexion's (FLXN) commercial launch of Zilretta seems well-timed keeping in view how rapidly the osteoarthritis market is growing worldwide.
Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.
Weak margins, declining year-over-year revenues and rising operating costs continue to pose challenges to GNC Holdings (GNC).
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
Patterson's (PDCO) dental segment sales have been weak. The company faces stiff competition from at least 15 full-service distributors and small distributors.
Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.
OPKO Health (OPK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.